[go: up one dir, main page]

WO1990006696A3 - Vaccin meningocoque de la proteine de la membrane externe de la classe 1 - Google Patents

Vaccin meningocoque de la proteine de la membrane externe de la classe 1 Download PDF

Info

Publication number
WO1990006696A3
WO1990006696A3 PCT/US1989/005678 US8905678W WO9006696A3 WO 1990006696 A3 WO1990006696 A3 WO 1990006696A3 US 8905678 W US8905678 W US 8905678W WO 9006696 A3 WO9006696 A3 WO 9006696A3
Authority
WO
WIPO (PCT)
Prior art keywords
membrane protein
protein vaccine
class
meningococcal class
meningococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1989/005678
Other languages
English (en)
Other versions
WO1990006696A2 (fr
Inventor
Robert C Seid
Peter R Paradiso
Jan T Poolman
Peter Hoogerhout
Emmanuel J H J Wiertz
Peter Van Der Ley
John Edward Heckels
Ian Nicholas Clarke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Praxis Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27352237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1990006696(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NL8803111A external-priority patent/NL8803111A/nl
Application filed by Praxis Biologics Inc filed Critical Praxis Biologics Inc
Priority to JP50166290A priority Critical patent/JP3436756B2/ja
Priority to EP90901397A priority patent/EP0449958B9/fr
Priority to DE68921895T priority patent/DE68921895T3/de
Publication of WO1990006696A2 publication Critical patent/WO1990006696A2/fr
Publication of WO1990006696A3 publication Critical patent/WO1990006696A3/fr
Priority to NO912369A priority patent/NO305463B1/no
Priority to DK199101174A priority patent/DK175788B1/da
Priority to FI912965A priority patent/FI113009B/fi
Anticipated expiration legal-status Critical
Priority to US08/204,808 priority patent/US7118757B1/en
Priority to US08/461,651 priority patent/US7238345B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Des vésicules de la membrane externe, des protéines de la membrane externe de classe 1 de Neisseria meningitidis, des fragments ou des oligopeptides contenant des épitopes des protéines de membrane externe de classe 1 peuvent être utilisés pour l'immunisation contre la maladie méningocoque.
PCT/US1989/005678 1988-12-19 1989-12-19 Vaccin meningocoque de la proteine de la membrane externe de la classe 1 Ceased WO1990006696A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP50166290A JP3436756B2 (ja) 1988-12-19 1989-12-19 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
EP90901397A EP0449958B9 (fr) 1988-12-19 1989-12-19 Vaccin meningocoque de la proteine de la membrane externe de la classe 1
DE68921895T DE68921895T3 (de) 1988-12-19 1989-12-19 Meningococcales klasse i-aussenmembranprotein-vakzin.
FI912965A FI113009B (fi) 1988-12-19 1991-06-18 Menetelmä rokotteen valmistamiseksi Neisseria meningitidis-bakteeria vastaan sekä Neisseria meningitidis -kanta
DK199101174A DK175788B1 (da) 1988-12-19 1991-06-18 Vaccine imod meningococcussygdomme, deri indgående komponenter, disses anvendelse og rekombinanter, som eksprimerer dem
NO912369A NO305463B1 (no) 1988-12-19 1991-06-18 FremgangsmÕte for fremstilling av en vaksine mot Neisseria meningitidis, klasse 2/3 minusmutant av Neisseria Neisseria meningitidis stamme, samt mikroorganisme som uttrykker et fusjonsprotein
US08/204,808 US7118757B1 (en) 1988-12-19 1994-02-15 Meningococcal class 1 outer-membrane protein vaccine
US08/461,651 US7238345B1 (en) 1988-12-19 1995-06-05 Recombinant microorganism expressing meningococcal class 1 outer membrane protein

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NL8803111A NL8803111A (nl) 1988-12-19 1988-12-19 Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
NL8803111 1988-12-19
NL8900036A NL8900036A (nl) 1988-12-19 1989-01-06 Multivalent meningococcen klasse 1 buitenmembraaneiwit vaccin.
NL8900030 1989-01-06
NL8901612A NL8901612A (nl) 1988-12-19 1989-06-26 Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
NL8901612 1989-06-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US07691005 A-371-Of-International 1989-12-19
US08/204,808 Continuation US7118757B1 (en) 1988-12-19 1994-02-15 Meningococcal class 1 outer-membrane protein vaccine

Publications (2)

Publication Number Publication Date
WO1990006696A2 WO1990006696A2 (fr) 1990-06-28
WO1990006696A3 true WO1990006696A3 (fr) 1990-07-12

Family

ID=27352237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/005678 Ceased WO1990006696A2 (fr) 1988-12-19 1989-12-19 Vaccin meningocoque de la proteine de la membrane externe de la classe 1

Country Status (10)

Country Link
EP (1) EP0449958B9 (fr)
JP (1) JP3436756B2 (fr)
AT (1) ATE120093T1 (fr)
AU (1) AU640118B2 (fr)
DE (1) DE68921895T3 (fr)
DK (1) DK175788B1 (fr)
ES (1) ES2070312T5 (fr)
FI (1) FI113009B (fr)
NO (1) NO305463B1 (fr)
WO (1) WO1990006696A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821521B1 (en) 1998-11-02 2004-11-23 Health Protection Agency Multicomponent meningococcal vaccine
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
DE69334197T2 (de) 1992-03-02 2008-12-11 Novartis Vaccines And Diagnostics S.R.L. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
AU683030B2 (en) * 1992-10-26 1997-10-30 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Immunization against (neisseria gonorrhoeae) and (neisseria meningitidis)
ES2145072T3 (es) 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
AU707131B2 (en) * 1995-08-04 1999-07-01 University Of Guelph Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
BR9610484A (pt) * 1995-09-18 2001-09-11 Us Army Medical Res Material C Processo para produção de vacinas de sub-unidades de proteosoma, não covalentemente complexadas e multivalentes
DK0909323T3 (da) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
GB9611673D0 (en) * 1996-06-05 1996-08-07 Peptide Therapeutics Ltd Meningococcal vaccine
JP4150082B2 (ja) 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9701489D0 (en) * 1997-01-24 1997-03-12 Auspharm Int Ltd Antigen
MX343744B (es) 1998-05-01 2016-11-22 J Craig Venter Inst Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
AU2003213540B8 (en) * 1998-05-29 2006-09-28 Novartis Vaccines And Diagnostic Inc. Combination meningitidis B/C vaccines
PT1741443E (pt) 1998-05-29 2014-07-31 Novartis Vaccines & Diagnostic Combinação de vacinas para a meningite b/c
EP1741443B1 (fr) * 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Vaccin B/C combiné contre la méningite
GB9814902D0 (en) * 1998-07-10 1998-09-09 Univ Nottingham Screening of neisserial vaccine candidates against pathogenic neisseria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6693186B2 (en) 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
EP1144643A1 (fr) * 1999-01-15 2001-10-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. Antigene de neisseria meningitidis
PT1228217E (pt) 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Antígenos de neisseria conservados
EP1069133A1 (fr) * 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions a base de Neisseria meningitidis et leur utilisation comme agents anti-infectieux
GB9916529D0 (en) * 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
AU784203B2 (en) * 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
EP1741784B1 (fr) * 1999-11-29 2010-03-10 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisseria à 85 kDa
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ATE269104T1 (de) * 1999-12-28 2004-07-15 Akzo Nobel Nv Salmonella impfstoff, der keinen antikörper gegen flagellin oder gegen flagella induziert
MXPA02006962A (es) * 2000-01-17 2002-12-13 Chiron Spa Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b.
PL216780B1 (pl) * 2000-01-25 2014-05-30 Univ Queensland Of Santa Lucia Wyizolowane białka zawierające konserwatywne obszary antygenu powierzchniowego NhhA z Neisseria meningitidis, białka fuzyjne, kompozycja farmaceutyczna, przeciwciało monoklonalne lub wiążący antygen fragment przeciwciała monoklonalnego, wyizolowany kwas nukleinowy, konstrukt ekspresyjny, komórka gospodarza, sposób wytwarzania rekombinowanego białka, sposób wykrywania N. meningitidis w próbce biologicznej, sposób diagnozowania zakażenia N. meningitidis oraz sposób wykrywania N. meningitidis w próbce biologicznej uzyskanej od pacjenta oraz zastosowanie wyizolowanego białka, białka fuzyjnego i konstruktu ekspresyjnego
AU3948801A (en) 2000-02-28 2001-09-12 Chiron Spa Heterologous expression of neisserial proteins
BRPI0112928B1 (pt) * 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AP1897A (en) * 2001-01-23 2008-10-10 Aventis Pasteur Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
AU2002252638A1 (en) 2001-04-17 2002-10-28 Children's Hospital Oakland Research Institute Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP1499712A4 (fr) 2002-04-12 2008-04-16 Melbourne Health Variants viraux de l'hepatite b presentant une sensibilite reduite aux analogues de nucleoside et utilisations desdits variants
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2775098T3 (es) 2002-10-11 2020-07-23 Glaxosmithkline Biologicals Sa Vacunas de polipéptidos para protección amplia contra linajes meningocócicos hipervirulentos
WO2004043407A2 (fr) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methodes et produits de traitement des infections staphylococciques
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN102319427A (zh) 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005042564A1 (fr) * 2003-10-20 2005-05-12 Sidney Kimmel Cancer Center Proteines de fusion flagelline, comme adjuvants ou vaccins, et procedes d'utilisation
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
AU2006208208B2 (en) 2005-01-27 2011-05-19 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
AU2006230802A1 (en) 2005-04-08 2006-10-12 Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
EP1874923A4 (fr) 2005-04-08 2010-08-04 Melbourne Health Variantes du virus de l'hépatite b présentant une résistance aux agents de nucléotide anti-virale et application de ces variantes
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP2245048B1 (fr) 2008-02-21 2014-12-31 Novartis AG Polypeptides fhbp à méningocoques
GB0809659D0 (en) * 2008-05-28 2008-07-02 Univ Nottingham Polypeptides
JP5723768B2 (ja) 2008-05-30 2015-05-27 ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用
EP3312158A1 (fr) 2008-07-21 2018-04-25 The Brigham and Women's Hospital, Inc. Procédés et compositions se rapportant à des bêta-1,6-glucosamine oligosaccharides synthétiques
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CA2776004A1 (fr) 2009-09-30 2011-04-07 Novartis Ag Expression de polypeptides fhbp meningococciques
JP5960055B2 (ja) 2009-10-27 2016-08-02 ノバルティス アーゲー 改変髄膜炎菌ｆＨＢＰポリペプチド
WO2012032498A2 (fr) 2010-09-10 2012-03-15 Novartis Ag Développements apportés à des vésicules membranaires externes méningococciques
JP2012090571A (ja) * 2010-10-27 2012-05-17 Sekisui Chem Co Ltd 動物の免疫方法、免疫用組成物、抗体の製造方法、並びに、ハイブリドーマの製造方法
BR112014031386A2 (pt) 2012-06-14 2017-08-01 Pasteur Institut vacinas para meningococos do sorogrupo x
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
US10870822B2 (en) * 2014-04-17 2020-12-22 Corning Incorporated Vessel for growth of biological entities
AU2015296555B2 (en) * 2014-07-30 2020-05-21 Genome Protection, Inc. Flagellin compositons and uses
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
US20240325517A1 (en) * 2020-09-15 2024-10-03 The University Of Montana Compositions and methods targeting filamentous bacteriophage

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090660A2 (fr) * 1982-03-30 1983-10-05 THE UNITED STATES OF AMERICA as represented by the Secretary of The United States Department of Commerce Vaccin anti-gonococcique
EP0145359A2 (fr) * 1983-11-21 1985-06-19 The Wellcome Foundation Limited Complexes, leur procédé de préparation et formulations les contenant
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0301992A2 (fr) * 1987-07-30 1989-02-01 Centro Nacional De Biopreparados Vaccin contre Neisséria meningitidis groupe B, gammaglobuline et facteur de transfert
WO1989010967A1 (fr) * 1988-05-05 1989-11-16 Praxis Biologics, Inc. Vaccins de flagelline recombinants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0090660A2 (fr) * 1982-03-30 1983-10-05 THE UNITED STATES OF AMERICA as represented by the Secretary of The United States Department of Commerce Vaccin anti-gonococcique
EP0145359A2 (fr) * 1983-11-21 1985-06-19 The Wellcome Foundation Limited Complexes, leur procédé de préparation et formulations les contenant
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
EP0301992A2 (fr) * 1987-07-30 1989-02-01 Centro Nacional De Biopreparados Vaccin contre Neisséria meningitidis groupe B, gammaglobuline et facteur de transfert
WO1989010967A1 (fr) * 1988-05-05 1989-11-16 Praxis Biologics, Inc. Vaccins de flagelline recombinants

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Biological Abstracts, Volume 87, 1989 H. ABDILLAHI et al.: "Microbiol. Immunol. 47(3): 139-144. 1988. Definition of Meningococcal Class 1 OMP Sybtyping Antigens by Monoclonal Antibodies", see Abstract No. 115445 *
Biological Abstracts/RRM, BR36:126147, AN 89:258923, E.J.H.J. WIERTZ et al.: "Human T-Cell Epitope Mapping of the Meningococcal Class 1 Outer Membrane Protein", Ici Pharmaceuticals-Ucla (University of California-Los Angeles) Symposium on Immunogenicity, Steamboat Springs, Colorado, USA, January 21-28, 1989. & J Cell Biochem Suppl 0 (13 Part A). 1989. 326. *
CHEMICAL ABSTRACTS, Volume 94, No. 25, 22 June 1981, American Chemical Society, (Columbus, Ohio, US), C.-M. TSAI et al.: "Five Structural Classes of Major Outer Membrane Proteins in Neisseria Meningitidis", see page 281* Abstract 205111z, & J. Bacteriol. 1981, 146(1), 69-78 (ENG)* *
Infection and Immunity, Volume 40, No. 1, April 1983, American Society for Microbiology, E.C. BEUVERY et al.: "Preparation and Physicochemical and Immunological Characterization of Polysaccharide-Outer Membrane Protein", pages 369-380 *
Infection and Immunity, Volume 46, No. 2, November 1984, American Society for Microbiology, L. WANG et al.: "Development of a Neisseria Meningitidis Group B Serotype 2b Protein Vaccine and Evaluation in a Mouse Model", pages 408-414 *
Infection and Immunity, Volume 54, No. 2, November 1986, American Society for Microbiology, W. JISKOOT et al.: "Immunogenic Activity of Gonococcal Protein I in Mice with Three Different Lipoidal Adjuvants Delivered in Liposomes", pages 333-338 *
Infection and Immunity, Volume 55, No. 11, November 1987, American Society for Microbiology, A.K. BARLOW et al.: "Molecular Cloning and Expression of Neisseria Meningitidis Class 1 Outer Membrane Protein in Escherichia Coli k-12", pages 2734-2740 *
Infection and Immunity, Volume 57, No. 3, March 1989, American Society for Microbiology, J.T. POOLMAN et al.: "Purification, Cyanogen Bromide Cleavage, and Amino Terminus Sequencing of Class 1 and Class 3 Outer Membrane Proteins of Memingococci", pages 1005-1007 *
Journal of Bacteriology, Volume 141, No. 1, January 1980, CHAO-MING TSAI et al.: "Chemical Analysis of Major Outer Membrane Proteins of Neisseria Meningitidis: Comparison of Serotypes 2 and 11", pages 169-176 *
Journal of Immunological Methods, Volume 113, 1988, Elsevier Science Publishers B.V. (Biomedical Division) E. WEDEGE et al.: "Restoration of Antibody Binding to Blotted Meningococcal Outer Membrane Proteins using Various Detergents", pages 51-59 *
Vaccine, Volume 5, No. 2, 5 June 1987, Butterworth & Co. (Publishers) Ltd, (Guildford, Surrey, GB), G. GREGORIADIS et al.: "Liposomes as Immunological Adjuvants: Antigen Incorporation Studies", pages 145-151 *
Vaccine, Volume 5, No. 4, 5 December 1987, Butterworth & Co. (Publishers) Ltd, (London, GB), T. TEERLINK et al.: "Synergistic Effect of Detergents and Aluminium Phosphate on the Humoral Immune Response to Bacterial and Viral Membrane Proteins", pages 307-314 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821521B1 (en) 1998-11-02 2004-11-23 Health Protection Agency Multicomponent meningococcal vaccine
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine

Also Published As

Publication number Publication date
FI912965A0 (fi) 1991-06-18
NO912369L (no) 1991-08-06
EP0449958A1 (fr) 1991-10-09
DE68921895D1 (de) 1995-04-27
EP0449958B2 (fr) 2002-11-13
ATE120093T1 (de) 1995-04-15
ES2070312T3 (es) 1995-06-01
EP0449958B1 (fr) 1995-03-22
NO305463B1 (no) 1999-06-07
DK175788B1 (da) 2005-02-21
AU640118B2 (en) 1993-08-19
ES2070312T5 (es) 2003-05-16
DE68921895T3 (de) 2003-05-22
FI113009B (fi) 2004-02-27
DE68921895T2 (de) 1995-09-07
JPH06503465A (ja) 1994-04-21
WO1990006696A2 (fr) 1990-06-28
AU4821990A (en) 1990-07-10
NO912369D0 (no) 1991-06-18
EP0449958B9 (fr) 2003-05-28
JP3436756B2 (ja) 2003-08-18
DK117491D0 (da) 1991-06-18
DK117491A (da) 1991-08-15

Similar Documents

Publication Publication Date Title
WO1990006696A3 (fr) Vaccin meningocoque de la proteine de la membrane externe de la classe 1
NO951181L (no) Immunogen menigokokk-LPS, ytter-membranvesikler, samt vaksine fremstilt derav
AU657487B2 (en) Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations
EP0117783A3 (fr) Vaccin couplé de l'haemophilus influenzae type B
EP1378245A3 (fr) Protéines de liaison de transferrine de neisseria gonorrhoeae et neisseria meningitidis. Leur utilisation comme vaccin
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
CA2014033A1 (fr) Compositions et traitement contre la pneumonie chez les animaux
DE69031351D1 (de) Zubereitungen und behandlungen von pneumonia in tieren
AU3313789A (en) Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine
CA2007248A1 (fr) Vaccin antimeningococcique de classe 1 contenant une proteine de la membrane exterieure du meningocoque
NO892015L (no) Fremgangsmaate for fremstilling av et legemiddel.
NO912823L (no) Fremgangsmaate for fremstilling av klasse ii-proteinet av neisseria meningitidis samt vaksiner som inneholder dette.
NO912822L (no) Fremgangsmaate for fremstilling av klasse ii-proteinet frayttermembranen til neisseria meningitidis.
NO912824L (no) Fremgangsmaate for fremstilling av klasse ii-proteinet frayttermembranen til neisseria meningitidis.
AU7614798A (en) High level expression, purification and refolding of the Neisseria meningitidis outer membrane group B porin proteins
ZA915627B (en) The class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties,and vaccines containing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990901397

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 912965

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1990901397

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990901397

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 912965

Country of ref document: FI